Jupiter Neurosciences Launches Nugevia™ Longevity Supplement Line to Drive Revenue and Address Growing Market

Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company, has launched Nugevia™, its direct-to-consumer longevity product line, marking a significant step in its strategy to harmonize drug development with consumer revenue generation. The launch addresses the booming scientifically backed longevity market, valued at $65 billion in 2023 and projected to reach $314 billion by 2030, with Jupiter Neurosciences estimating the combined mind, beauty, and energy addressable market at $8 trillion. Nugevia leverages JOTROL™, an enhanced orally administered resveratrol formulation with antioxidant and anti-inflammatory effects, backed by over eight years of pharmaceutical development and designed to deliver therapeutically relevant, safe levels of resveratrol.

The first three Nugevia formulations target mitochondrial support, mental clarity, and beauty from within, featuring precision-engineered intelligent stacking of synergistic compounds to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. Nugevia GLO is a daily supplement for radiant, resilient skin, Nugevia PWR supports cellular energy and endurance, and Nugevia MND protects and enhances cognitive function, all available directly to consumers this fall. Christer Rosen, Chairman and CEO of Jupiter Neurosciences, emphasized the personal importance of the cognitive product, citing family and former colleague experiences with neurodegenerative diseases, and stated that the launch translates science into broad, real-world impact with unmatched bioavailability and scientific credibility.

To build brand awareness, Jupiter Neurosciences has named professional golfer Annika Sörenstam as its first brand ambassador, leveraging her long career and advocacy for healthy aging to promote Nugevia's science-backed approach. This direct-to-consumer model allows the company to generate immediate revenue, reducing dependency on the slower clinical drug development process, which can take years from development to market. By combining pharmaceutical rigor with consumer accessibility, Jupiter Neurosciences aims to invigorate its business and capitalize on the growing demand for longevity and wellness products.